NCT07108114招募中1 期
A Phase 1 Dose-Escalation Study of SLV-324 in Subjects With Metastatic Solid Tumors
Solve Therapeutics12 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2025年8月25日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 70
- 试验地点
- 12
- 主要终点
- MTD or RDR
研究概览
简要总结
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects with metastatic solid tumors.
详细描述
A Bayesian optimal interval (BOIN) design with a target dose-limiting toxicity (DLT) rate for the maximum tolerated dose (MTD) of 27% and an estimated maximum sample size of ~70 subjects will be used to guide the dose escalation and determine the recommended dosing regimen (RDR) of SLV-324.
SLV-324 will be administered intravenously (IV) in repeated cycles. Treatment will continue until progressive disease or discontinuation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women (as appropriate for cancer type) of age ≥18 years.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or
- •Histologically or cytologically confirmed diagnosis of solid tumor as documented in medical records.
- •Presence of metastatic disease that has progressed during or following previous treatment.
- •Presence of radiographically measurable disease.
- •Prior receipt of commercially available therapies that are indicated for the subject's cancer and have demonstrated survival benefit for that indication.
- •Availability of tumor tissue from a fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival tumor sample from a previous biopsy.
- •Availability of computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and pelvis, and/or fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT (if appropriate for tumor type) (with PET from base of the skull to mid-thigh, if performed) within 35 days before study drug administration.
- •Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before the start of study drug administration.
- •Adequate hematological profile.
- •Adequate coagulation profile.
- •Adequate hepatic profile.
- •Adequate renal function.
- •Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection.
- •For female subjects of childbearing potential, a negative serum pregnancy test.
- •For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until ≥6 months after the final dose of study therapy.
- •For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥6 months after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥12 months after administration of the final dose of study therapy.
- •Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including required tumor biopsy/aspirations and/or radiographic studies), and study restrictions.
- •Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.
排除标准
- •Malignancy involving the central nervous system unless brain metastases have been previously treated with radiotherapy, have been stable for ≥4 weeks, and do not require corticosteroids.
- •Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
- •Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.
- •Significant cardiovascular event or comorbidity.
- •Significant screening ECG abnormalities.
- •Pregnancy or breastfeeding.
- •Major surgery within 4 weeks before the start of study therapy.
- •Use of a strong inhibitor or inducer of CYP3A4 or CYP1A
- •Use of a drug known to prolong the QT interval within 7 days prior to the start of study drug administration.
- •Concurrent participation in another therapeutic or imaging clinical trial.
- •Other conditions likely to interfere with a subject's ability to participate in the study.
研究组 & 干预措施
SLV-324 intravenous (IV infusion)
Experimental
SLV-324 will be administered at different dose levels in dose-escalation cohorts and at the RDR in dose expansion cohorts
干预措施: SLV-324 intravenous (IV infusion) (Drug)
结局指标
主要结局
MTD or RDR
时间窗: Through the duration of treatment, up to approximately 18 months
Determination of the MTD (maximum tolerated dose) and/or RDR (recommended dosing regimen) for SLV-324
次要结局
- SLV-324 Administration as Assessed by Prescribing Records(Through the duration of treatment, up to approximately 18 months)
- SLV-324 Safety(Up to approximately 18 months.)
- Evaluation of use of supportive care and other concomitant medications(Through the duration of treatment, up to approximately 18 months)
- SLV-324 Pharmacokinetics: Maximum Concentration (Cmax)(Varying timepoints through the duration of treatment, up to approximately 18 months)
- Immunogenicity(Varying timepoints through the duration of treatment, up to approximately 18 months)
- Objective Response Rate (ORR)(Through the duration of treatment, up to approximately 18 months)
- Time to Response (TTR)(Up to approximately 36 months)
- Duration of Response (DOR)(Up to approximately 36 months.)
- Progression-free Survival (PFS)(Up to approximately 36 months)
- Time to Treatment Failure (TTF)(Up to approximately 36 months)
- Overall Survival (OS)(Up to approximately 36 months)
- SLV-324 Pharmacokinetics: Time to Maximum Concentration (Tmax)(Varying timepoints through the duration of treatment, up to approximately 18 months)
- SLV-324 Pharmacokinetics: Area Under the Curve (AUC)(Varying timepoints through the duration of treatment, up to approximately 18 months)
- SLV-324 Pharmacokinetics: half-life ( t1/2)(Varying timepoints through the duration of treatment, up to approximately 18 months)
研究者
研究点 (12)
Loading locations...
相似试验
进行中（未招募）
1 期
EXtended CriteriA treatment for LIver Metastases with heavy tumour BURdeEUCTR2019-002388-87-NOOslo University Hospital39
已完成
2 期
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)jRCT2080224605Merck Biopharma Co., Ltd. Japan141
已完成
不适用
Treatment of poor prognosis metastatic teratomaMetastatic teratomaCancerISRCTN14535482Medical Research Council (MRC) (UK)154
已完成
不适用
Assessment of the Safety and Efficacy of Intra-Arterial Liver Isolation Chemotherapy Using an Implantable Vascular Access System1. Secondary hepatic metastases from colorectal cancer2. Hepatocellular carcinoma1. Secondary hepatic metastases from colorectal cancer2. Hepatocellular carcinomaCancer - LiverACTRN12611001273976Dr Rodney Lane10
进行中（未招募）
不适用
Treatment of locally advanced or metastatic non-small cell lung cancer with Pemetrexed (Alimta) and Gemcitabine or Gemcitabine and Carboplatin: The PAGe study. - The PAGe studyEUCTR2005-001577-97-SEGunnar Hillerdal96